Navigation Links
Astellas Adds CNS Therapy Area Leader to Global R&D Team
Date:6/4/2009

DEERFIELD, Ill., June 4 /PRNewswire/ -- Astellas Pharma Global Development ("APGD"), a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that Dr. Betsy Garofalo has been hired as the global therapy area leader for CNS. Garofalo is a pediatric neurologist and epileptologist bringing the team more than 17 years of drug development experience.

"Betsy's charge as head of the global therapy area is to provide strategic direction and leadership for the development of all Astellas CNS compounds," said Dr. Steven Ryder, president of APGD. "Betsy's deep experience in CNS disorders and past successes make her an excellent choice to help us develop new medications for the many patients with unmet medical needs."

In addition to her work at Astellas, Garofalo is an adjunct associate professor of pediatrics at the University of Michigan. In 2007, Garofalo formed the Michigan Technology and Research Institute where she provided consulting services to the pharmaceutical industry. Before that, Garofalo held numerous positions of leadership at Parke-Davis and then Pfizer Research and Development. She received her medical training and completed a pediatric residency at the Indiana University School of Medicine followed by a fellowship in neurology/pediatric neurology and a fellowship in epilepsy at the University of Michigan.

About Astellas

Astellas Pharma Global Development, located in Deerfield, Illinois, is a group company of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. For more information about Astellas Pharma Inc., please visit the website at www.astellas.com/en/.


'/>"/>
SOURCE Astellas Pharma Global Development
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Astellas Hires New Vice President of Compliance
2. Astellas Announces New Vice President of Marketing
3. Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
4. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
5. FDA Approves Additional Indication for Astellas MYCAMINE(R)
6. Cardiome And Astellas Announce Regulatory Update
7. Pausing Hormone Therapy Doesnt Cut Mammogram Recalls
8. Oxygen + MRI might help determine cancer therapy success, researchers find
9. QLT announces positive results from the evaluation of Visudyne(R) combination therapy
10. New Journal of Natural Medicine Launched This June, Promotes Natural Therapy
11. New Data Support Use of Simple Test to Predict Endometrial Cancer Response to Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in post-acute health care, have expanded their existing home health joint venture through ... AccentCare has been operating a joint venture home health company with Asante, delivering ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... ... presenting the latest in wound care advancements to physician colleagues, skilled nursing facility ... is titled, "Navigating the Treacherous Waters of Wound Care." , "At many of ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... DIEGO , Oct. 12, 2017 AVACEN ... recognized the company with their  2017 New Product Innovation Award ... based on extensive primary and secondary medical device market research ... Medical, through its first-to-market OTC, drug-free pain relief product, the ... unique approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE ... team that developed an innovative way to use nonlinear ... the delivery of new drugs. ... Clinical Dermatology Conference will show how researchers from BioPharmX ... Harvard Medical School used a suite of imaging techniques ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
Breaking Medicine Technology: